NYMC Faculty Publications

Receipt of Palivizumab Before Birth Hospitalization Discharge Among Preterm Infants in the United States

Author Type(s)

Faculty

DOI

10.1055/s-0034-1543951

Journal Title

American Journal of Perinatology

First Page

1017

Last Page

1023

Document Type

Article

Publication Date

9-1-2015

Department

Otolaryngology

Second Department

Neurosurgery

Keywords

Antiviral Agents, Databases, Factual, Female, Gestational Age, Hepatitis B Vaccines, Hospitalization, Humans, Infant, Infant, Newborn, Infant, Premature, Logistic Models, Male, Palivizumab, Patient Discharge, Respiratory Syncytial Virus Infections, Retrospective Studies, United States, Vitamin K

Disciplines

Medicine and Health Sciences

Abstract

OBJECTIVE: This study aims to determine predischarge palivizumab receipt prevalence among infants ≤ 36 weeks' gestational age.

STUDY DESIGN: This retrospective cohort study used hospital discharge records from the Premier Perspective database (Premier Inc., Charlotte, NC) of infants ≤ 36 weeks' gestational age who were discharged home after birth hospitalization during the November-March respiratory syncytial virus (RSV) seasons from 2006 to 2011. Descriptive statistics were performed and logistic regression was employed to identify differences in categorical variables.

RESULTS: Among infants ≤ 36 weeks' gestational age discharged home during the RSV seasons, 21.4 to 27.0% had a record of palivizumab receipt before discharge. Among infants ≤ 30 weeks' gestational age, palivizumab receipt was 82.3 to 88.8%. Receipt varied considerably at the hospital level, from 0 to 100%.

CONCLUSION: This study improves our understanding of characteristics associated with predischarge palivizumab administration. The identified gaps in recommended care can help inform future implementation of palivizumab and other interventions to help improve the health of high-risk preterm infants in the United States.

Link to Full Text

Share

COinS